Umberto Barbaresi, Mauro Dicuio, Federico Mineo Bianchi, Manola Marini, Francesca Quadrini, Santo Lupo, Roberta De Stefano
{"title":"Serenoa repens脂质甾醇提取物单独或与蜂胶多酚和serrata Boswellia提取物栓剂合用对下尿路疾病患者PSA水平和症状的影响","authors":"Umberto Barbaresi, Mauro Dicuio, Federico Mineo Bianchi, Manola Marini, Francesca Quadrini, Santo Lupo, Roberta De Stefano","doi":"10.4081/aiua.2025.13877","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Standard medical treatments for patients with uncomplicated LUTS include alpha-blockers, 5-alpha-reductase inhibitors (5ARIs), phosphodiesterase type 5 inhibitors, antimuscarinics, and beta-3 agonists. The lipido-sterolic extract of Serenoa repens (Sr) is also recommended as a therapeutic option. Our study prospectively evaluated the impact of a 6-month assumption of lipido-sterolic extract of Sr alone or in combination with Phenolmicin P3 and Bosexil medical devices suppositories on symptoms and on PSA levels in patients affected by BPO related-LUTS.</p><p><strong>Methods: </strong>We prospectively enrolled 509 patients: 194 (group 1) were prescribed only a 6-month assumption of Sr extract, while 315 (group 2) were also prescribed a 20-day therapy with Phenolmicin P3 and Bosexil medical devices suppositories.</p><p><strong>Results: </strong>After 6 months, 371 patients' data were registered and analyzed. Furthermore, patients' withdrawal and motivations were also considered.</p><p><strong>Conclusions: </strong>In our clinical study, the patients treated with Sr extract (320 mg daily) showed a significant relief regarding LUTS, and the association of a 6-month assumption of Sr extract with a 20-day prescription of Phenolmicin P3 and Bosexil medical device in suppository form seems to significantly improve both efficacy on LUTS and decrease of PSA levels.</p>","PeriodicalId":46900,"journal":{"name":"Archivio Italiano di Urologia e Andrologia","volume":"97 3","pages":"13877"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of <i>Serenoa repens</i> lipido-sterolic extract alone or in combination with propolis polyphenols and <i>Boswellia serrata</i> extract suppositories on PSA level and symptoms in patients affected by lower urinary tract disorders.\",\"authors\":\"Umberto Barbaresi, Mauro Dicuio, Federico Mineo Bianchi, Manola Marini, Francesca Quadrini, Santo Lupo, Roberta De Stefano\",\"doi\":\"10.4081/aiua.2025.13877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Standard medical treatments for patients with uncomplicated LUTS include alpha-blockers, 5-alpha-reductase inhibitors (5ARIs), phosphodiesterase type 5 inhibitors, antimuscarinics, and beta-3 agonists. The lipido-sterolic extract of Serenoa repens (Sr) is also recommended as a therapeutic option. Our study prospectively evaluated the impact of a 6-month assumption of lipido-sterolic extract of Sr alone or in combination with Phenolmicin P3 and Bosexil medical devices suppositories on symptoms and on PSA levels in patients affected by BPO related-LUTS.</p><p><strong>Methods: </strong>We prospectively enrolled 509 patients: 194 (group 1) were prescribed only a 6-month assumption of Sr extract, while 315 (group 2) were also prescribed a 20-day therapy with Phenolmicin P3 and Bosexil medical devices suppositories.</p><p><strong>Results: </strong>After 6 months, 371 patients' data were registered and analyzed. Furthermore, patients' withdrawal and motivations were also considered.</p><p><strong>Conclusions: </strong>In our clinical study, the patients treated with Sr extract (320 mg daily) showed a significant relief regarding LUTS, and the association of a 6-month assumption of Sr extract with a 20-day prescription of Phenolmicin P3 and Bosexil medical device in suppository form seems to significantly improve both efficacy on LUTS and decrease of PSA levels.</p>\",\"PeriodicalId\":46900,\"journal\":{\"name\":\"Archivio Italiano di Urologia e Andrologia\",\"volume\":\"97 3\",\"pages\":\"13877\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archivio Italiano di Urologia e Andrologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/aiua.2025.13877\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivio Italiano di Urologia e Andrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/aiua.2025.13877","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Efficacy of Serenoa repens lipido-sterolic extract alone or in combination with propolis polyphenols and Boswellia serrata extract suppositories on PSA level and symptoms in patients affected by lower urinary tract disorders.
Background: Standard medical treatments for patients with uncomplicated LUTS include alpha-blockers, 5-alpha-reductase inhibitors (5ARIs), phosphodiesterase type 5 inhibitors, antimuscarinics, and beta-3 agonists. The lipido-sterolic extract of Serenoa repens (Sr) is also recommended as a therapeutic option. Our study prospectively evaluated the impact of a 6-month assumption of lipido-sterolic extract of Sr alone or in combination with Phenolmicin P3 and Bosexil medical devices suppositories on symptoms and on PSA levels in patients affected by BPO related-LUTS.
Methods: We prospectively enrolled 509 patients: 194 (group 1) were prescribed only a 6-month assumption of Sr extract, while 315 (group 2) were also prescribed a 20-day therapy with Phenolmicin P3 and Bosexil medical devices suppositories.
Results: After 6 months, 371 patients' data were registered and analyzed. Furthermore, patients' withdrawal and motivations were also considered.
Conclusions: In our clinical study, the patients treated with Sr extract (320 mg daily) showed a significant relief regarding LUTS, and the association of a 6-month assumption of Sr extract with a 20-day prescription of Phenolmicin P3 and Bosexil medical device in suppository form seems to significantly improve both efficacy on LUTS and decrease of PSA levels.